Skip to content Skip to footer
Subscribe Now

NEWS

Merus and Biohaven Join Forces to Advance Three Bispecific ADC Programs
Shots: Biohaven & Merus have entered into a research collaboration & license agreement to co-develop bispecific ADCs using the former’s ADC conjugation & payload platform plus Merus’ Biclonics tech platform As per the terms, Biohaven will develop preclinical ADCs for 3 Merus’ BsAbs (2 developed via Biclonics & 1 in preclinical) & each is…
January 13, 2025
Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio
Shots: Veralox has signed an exclusive agreement to acquire Nudge Therapeutics & its preclinical cyclic AMP-GMP (cGAS) inhibitors. The financial terms were undisclosed As per the terms, Veralox will resume the development of acquired candidates & initiate acquisition upon achievement of downstream milestones In addition, Veralox is developing VLX-1005 (12-LOX inhibitor) for thrombosis linked…
January 10, 2025
Astellas
Astellas Reports the Health Canada’s Approval of Vyloy (Zolbetuximab) Plus Chemotherapy for Advanced G/GEJ Cancer
Shots: The Health Canada has approved Vyloy + fluoropyrimidine & Pt-based CT as a 1L treatment of locally advanced unresectable or metastatic CLDN 18.2+/HER2-ve G/GEJ adenocarcinoma, with further submissions under review. In addition, Canada’s Drug Agency (CDA-AMC) recommended reimbursement of Vyloy with conditions Approval was based on the P-III (SPOTLIGHT: n= 565 & GLOW:…
January 10, 2025
Transcarent to Acquire Accolade for ~$621M
Shots: Transcarent to acquire Accolade with a total equity value of ~$621M, with shareholders receiving $7.03/share in cash, making Accolade private. Closing expected in Q2’25 The acquisition will yield a unified platform with Transcarent’s WayFinding (generative AI), pharmacy benefits & overall care experiences (incl. weight health, cancer & surgery care) & Accolade’s data of…
January 9, 2025
Vividion Therapeutics to Bolster its Genomic Abilities Through the Acquisition of Tavros Therapeutics
Shots: Vividion (Bayer’s subsidiary) has acquired Tavros to strengthen its genomic capabilities via Tavros’ platform. The financial terms are undisclosed The acquisition strengthens Vividion’s functional genomics expertise by adding proprietary genomic screening approaches to discover new targets & translate the known ones. Combining resources from both the companies will enable drug discovery in oncology…
January 9, 2025
Load more